Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
89 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Smallpox - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Smallpox - Pipeline Review, H2 2014', provides an overview of the Smallpox's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Smallpox - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Smallpox and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Smallpox products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Smallpox pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Smallpox Overview 8 Therapeutics Development 9 Pipeline Products for Smallpox - Overview 9 Pipeline Products for Smallpox - Comparative Analysis 10 Smallpox - Therapeutics under Development by Companies 11 Smallpox - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Smallpox - Products under Development by Companies 17 Smallpox - Companies Involved in Therapeutics Development 18 Inovio Pharmaceuticals, Inc. 18 Bavarian Nordic A/S 19 Symphogen A/S 20 Nanotherapeutics, Inc. 21 CEL-SCI Corporation 22 SIGA Technologies, Inc. 23 TapImmune Inc. 24 CJ CheilJedang Corp. 25 MacroGenics, Inc. 26 AlphaVax, Inc. 27 EpiVax, Inc. 28 Chimerix, Inc. 29 Conkwest, Inc. 30 Inhibikase Therapeutics, Inc. 31 Polyrizon Ltd. 32 Smallpox - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 43 smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 CJ-50300 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 brincidofovir - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Sym-002 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 cidofovir - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CEL-1000 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 tecovirimat - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 DNA Vaccine for Smallpox - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Smallpox Vaccine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 CST-102 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 DNA Vaccine for Smallpox - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 TPIV-300 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 imatinib mesylate - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Monoclonal Antibody for Infectious Disease - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 PL-801 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Smallpox Vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Smallpox - Recent Pipeline Updates 65 Smallpox - Dormant Projects 78 Smallpox - Discontinued Products 79 Smallpox - Product Development Milestones 80 Featured News & Press Releases 80 Apr 22, 2014: Bavarian Nordic Announces Execution of Option on Freeze-Dried IMVAMUNE 80 Nov 22, 2013: Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine 80 Nov 15, 2013: Bavarian Nordic Completes Delivery of 20 Million Doses of IMVAMUNE Smallpox Vaccine to the U.S. Strategic National Stockpile 81 Aug 07, 2013: Bavarian Nordic Receives European Marketing Authorization for IMVANEX Smallpox Vaccine 82 Jun 03, 2013: Chimerix And BARDA Continue Collaboration On Development Of CMX001 As Medical Countermeasure Against Smallpox 83 May 31, 2013: Bavarian Nordic's Imvanex Vaccine Receives Positive CHMP Opinion For Active Immunization Against Smallpox 84 May 29, 2013: SIGA Completes Second Delivery Of Arestvyr Under BARDA Contract 84 May 26, 2013: PharmAthene Announces Delaware Supreme Court Upholds Lower Court Ruling In Lawsuit Against SIGA Technologies 85 May 16, 2013: Chimerix Presents Data On CMX001 At 26th International Conference On Antiviral Research 85 Apr 16, 2013: Bavarian Nordic Receives Contract Valued Up To $228m From BARDA Securing Continued Production And Deliveries Of Imvamune Smallpox Vaccine 86 Appendix 88 Methodology 88 Coverage 88 Secondary Research 88 Primary Research 88 Expert Panel Validation 88 Contact Us 89 Disclaimer 89
List of Tables Number of Products under Development for Smallpox, H2 2014 9 Number of Products under Development for Smallpox - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Comparative Analysis by Unknown Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Smallpox - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 18 Smallpox - Pipeline by Bavarian Nordic A/S, H2 2014 19 Smallpox - Pipeline by Symphogen A/S, H2 2014 20 Smallpox - Pipeline by Nanotherapeutics, Inc., H2 2014 21 Smallpox - Pipeline by CEL-SCI Corporation, H2 2014 22 Smallpox - Pipeline by SIGA Technologies, Inc., H2 2014 23 Smallpox - Pipeline by TapImmune Inc., H2 2014 24 Smallpox - Pipeline by CJ CheilJedang Corp., H2 2014 25 Smallpox - Pipeline by MacroGenics, Inc., H2 2014 26 Smallpox - Pipeline by AlphaVax, Inc., H2 2014 27 Smallpox - Pipeline by EpiVax, Inc., H2 2014 28 Smallpox - Pipeline by Chimerix, Inc., H2 2014 29 Smallpox - Pipeline by Conkwest, Inc., H2 2014 30 Smallpox - Pipeline by Inhibikase Therapeutics, Inc., H2 2014 31 Smallpox - Pipeline by Polyrizon Ltd., H2 2014 32 Assessment by Monotherapy Products, H2 2014 33 Number of Products by Stage and Target, H2 2014 35 Number of Products by Stage and Mechanism of Action, H2 2014 37 Number of Products by Stage and Route of Administration, H2 2014 39 Number of Products by Stage and Molecule Type, H2 2014 42 Smallpox Therapeutics - Recent Pipeline Updates, H2 2014 65 Smallpox - Dormant Projects, H2 2014 78 Smallpox - Discontinued Products, H2 2014 79
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
